Romosozumab Versus Denosumab in Glucocorticoid-induced Osteoporosis: an Extended Observation of a Randomized Controlled Trial at 48 Months

NCT06472050 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

54

Enrollment

OTHER_GOV

Sponsor class

Conditions

Osteoporosis
Glucocorticoids Toxicity

Interventions

DRUG: Romosozumab
DRUG: Denosumab

Sponsor

Tuen Mun Hospital